High tumor mutation burden identifies tumors with a greater number of variants that may be more easily recognized by the immune system, which has been correlated with benefit from anti-PD-1/anti-PD-L1 therapies for cancers such as melanoma and NSCLC [32]. Here, CD274 is linked to cancer.